Document is current
Any future updates will be listed below
-
Authors
Gersing, Sarah
Cagiada, Matteo
Gebbia, Marinella
Gjesing, Anette P.
Coté, Atina G.
Seesankar, Gireesh
Li, Roujia
Tabet, Daniel
Weile, Jochen
Stein, Amelie
Gloyn, Anna L.
Hansen, Torben
Roth, Frederick P.
Lindorff-Larsen, Kresten
Hartmann-Petersen, Rasmus https://orcid.org/0000-0002-4155-7791
-
Funding
Funding for this research was provided by:
Novo Nordisk Fonden (PRISM, PRISM, PRISM, PRISM)
Lundbeckfonden (R272-2017-452, R209-2015-3283)
Canadian Institutes of Health Research (Foundation Grant)
Wellcome Trust (200837)
National Institute of Diabetes and Digestive and Kidney Diseases (U01-DK105535; U01-DK085545, UM1-DK126185)
Natur og Univers, Det Frie Forskningsråd (https://doi.org/10.46540/2032-00007B)
National Institutes of Health National Genome Research Institute (Center of Excellence in Genomic Science Initiative (HG010461))
National Institutes of Health National Human Genome Research Institute (Impact of Genomic Variation on Function (IGVF) Initiative (HG011989))
Royal Library, Copenhagen University Library
- License Information
-
More Information
Article History
Received: 14 July 2022
Accepted: 10 April 2023
First Online: 26 April 2023
Declarations
:
: Not applicable.
: Not applicable.
: F.P.R. is a shareholder and advisor for SeqWell, Constantiam, BioSymetrics, and a shareholder of Ranomics, and his lab has received research support from Alnylam, Deep Genomics, Beam Therapeutics and Biogen, Inc. A.L.G.'s spouse holds stock options in Roche and is an employee of Genentech.
